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ABSTRACT
Objective:
Our objective was to identify the patterns of opioid use among pregnant women enrolled
in RI Medicaid.
Methods
This study used linked RI Medicaid and RI Birth Certificate data from 01/01/2006 to
12/31/2016. We examined temporal trends of prescription opioid dispensings and
identified risk factors associated with opioids use during pregnancy.
Results
Among 25,500 RI Medicaid enrolled pregnant women who delivered a live baby from
2008 to 2016, 1,914 (7.5%) received at least one prescription for an opioid medication
during pregnancy, 810 (3.2%) were during the first trimester, 633 (2.5%) during the
second trimester, and 866 (3.4%) during the third trimester. Of these, 213 (0.8%)
women received 3 or more opioids during pregnancy. The prevalence of prescription
opioids dispensed in pregnant women increased from 4.9% in 2008 to 9.6% in 2015
(β±SD: 0.66±0.28, P=0.05).
Conclusions
Prescription opioid use during pregnancy has increased among women enrolled in RI
Medicaid.

KEYWORDS: opioid analgesics, pregnant women, RI Medicaid
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INTRODUCTION
While gestational opioid use may be associated with increased risk of maternal, fetal,
and neonatal complications,1,2 there are few studies regarding the opioid use in
pregnant women. It is important to investigate the extent of opioid use during pregnancy
to gain insight into the potential risk of maternal opioid exposure on mother and infant
health. We therefore assessed the use of prescription opioids in a cohort of Medicaidenrolled pregnant women in Rhode Island. This population is highly relevant as Rhode
Island has been disproportionately affected by opioid overuse and addiction as it is
among the top ten states with the highest rate of opioid overdose deaths.3 In RI the
number of substance-affected newborns and babies diagnosed with NAS has more than
doubled from 44/10,000 in 2005 to 94/10,000 in 2016.4 Further, research has shown
that patients who were opioid abuse or dependence are more likely to be insured thru
Medicaid than a private insurance company (76.1% vs. 42.8% Nationally).5 With
covering 30% of the population and 25% of that being women of childbearing age, RI
Medicaid is an important data source to investigate the impact of the opioid epidemic on
pregnant women.

The goal of this study was to determine the prevalence of prescription opioid use among
pregnant women enrolled in the Rhode Island (RI) Medicaid program and to
characterize use over time and by types of and intensity of opioid medication
prescribed.
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METHOD
Data Source
This retrospective cohort study evaluated linked RI Medicaid and RI Birth Certificate
data from January 1, 2006 to December 31, 2016. Deidentified Medicaid medical
information was provided by RI Executive Office of Human & Health Service (EOHHS).
These data were comprised of eligibility, medical, and prescription drug records for
health care services from inpatient hospitals, outpatient clinics, emergency rooms, and
pharmacies. Demographic information for enrolled members include age, gender, race,
and location of residency. To validate the pregnancy (exposure) period, we ascertained
pregnancy outcomes using birth certificate data provided by the RI Department of
Health (RIDOH), which collects these data within 24 to 48 hours after delivery. The data
were linked by RI EOHHS and RIDOH then subsequently deidentified for third-party
research purposes. This study was approved by the Institutional Review Board at the
RIDOH and University of Rhode Island.

Study Cohort
We included mothers enrolled in RI Medicaid who had a live birth occurring between
July 01 2006 to December 31 2016. Mothers who had a diagnosis of cancer pre- or
post-delivery or were dispensed opioids (methadone or buprenorphine) for Opioid Use
Disorder (OUD) during pregnancy were excluded from the study.

Exposure Window
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Gestational age was derived through ultrasound examination of mothers and included in
RIDOH birth certificate data. The conception date was estimated by subtracting the
infant’s gestational age, derived through ultrasound examination of mothers. The first 6
months prior to the conception date was evaluated for baseline opioid utilization. The
pregnancy window included the period from conception date through delivery date.
Prescription opioid exposure was evaluated 14 days prior to the conception date
through delivery date to encompass the possible residual effects of opioid use during
the conception period. Opioid use was assessed between January 01 2008 and
December 31 2015 to compare the full year utilization rate.

Prescription Opioid Exposure
Prescription opioid exposure during pregnancy was obtained through pharmacy records
using Therapeutic Class Code for filled prescription opioids, and using the number of
days for which the medication was supplied to determine if exposure occurred during
the pregnancy window. The prescription opioids considered in this study included
hydrocodone, oxycodone, codeine, morphine, and tramadol, which were the most
commonly prescribed opioids for RI Medicaid covered pregnant women.

Opioid exposure was defined as any one receipt of a prescription opioid dispensed
during the pregnancy exposure window; including opioids dispensed before the
exposure window with days supply extending to cover at least 1 day within the exposure
window. Average days of supply and daily doses were calculated. The daily doses for
each opioid prescription were converted to Morphine Milligram Equilibrium (MME) using
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the Center for Disease Control (CDC) conversion Table (2016 version). Further
investigation was conducted to determine the pattern of prescription opioids filled in
three pregnancy trimesters.

Comparison Group
To identify the risk factors associated with opioid use during pregnancy, we selected a
comparison group that included women without any opioid dispensings during
pregnancy.

Baseline Characteristics
Maternal characteristics at baseline included: age, race, substance use and abuse,
tobacco use, alcohol use, preexisting conditions, pain conditions, psychiatric
medications use, and opioid use at baseline. The operational definitions for the medical
covariates, including substance use and abuse, tobacco use, and alcohol use, are
described in Appendix Table 1.

Statistical Analyses
Descriptive analyses of prescription opioid dispensings, temporal trends, and
corresponding demographic and clinical characteristics were conducted. Continuous
variables were presented as mean ± standard deviation (SD) and compared using a
student t test. Categorical variables were presented as frequency (%) and compared
using a chi-square test or Fisher exact test depending upon the sample size in each
level. A multivariate logistic regression model was developed to identify significant risk
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factors associated with opioid use during pregnancy. Statistical significance was set up
at p≤ 0.05. All statistical analyses were conducted using SAS 9.4 (Cary, NC).

RESULTS
Of the total included 25,500 pregnancies, 1,914 (7.5%) received a total of 4,046 opioid
prescriptions at any time during their pregnancy, 810 (3.2%) received a prescription for
an opioid medication during their first trimester, 633 (2.5%) during their second
trimester, and 866 (3.4%) during their third trimester. Only 213 (0.8%) pregnancies were
identified with dispensings of more than 3 prescriptions for opioid medication.

Among those with opioid use during the 6-month period preceding pregnancy, the
leading documented pain-related indications included: abdominal pain (27%), back pain
(30%), or headache (18%). Among those with opioid use during the pregnancy period
the leading documented pain-related indications included: antepartum conditions or
complications (66%), abdominal pain (38%), back pain (36%), or headache (24%).

Figure 1 shows the temporal trend of prescription opioid use during pregnancy from
January 01, 2008 to December 31, 2015. The percentage of pregnancies with a
dispensed opioid increased significantly from 4.9% in 2008 to 11.1% in 2015 (Slope β ±
SE: 0.9 ± 0.2, p = 0.01), with sharp increases occurring in 2011 (145% from the
previous year) and 2012 (43% from the previous year).
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The most commonly dispensed opioids were hydrocodone, oxycodone, codeine, and
tramadol, respectively (Figure 2). Hydrocodone was the most frequently dispensed
opioid for all years (39-47% of prescription opioids) except 2008, for which oxycodone
use was more prevalent (39%). Four types of opioids (hydrocodone, oxycodone,
codeine and tramadol) accounted for nearly all prescription opioid use between 2011 2015, while use of other opioid types including morphine and hydromorphone dissipated
after 2010.

The average days of supply for prescription opioids dispensed was 9.3 days ± 9.4
(mean±SD). We did not observe a statistically significant trend in change in days supply
from 2008 to 2015. The average days of supply and MME for four commonly dispensed
opioids are listed in Table 1.

Demographic and clinical characteristics were assessed during the 6-month baseline
window and compared between women with and without opioid dispensing during
pregnancy (Table 2). Women with opioid dispensings during pregnancy were observed
to be younger (<18: 41% vs 34%, p<.0001), of white race (64% vs 52%, p <.0001), had
higher rates of tobacco (6.2% vs 2.2%, p<.0001), alcohol (7% vs 1%, p<.001), or
cocaine use (0.4% vs 0.07%, p<.0001), a higher rate of chronic pain diagnoses (e.g.
fibromyalgia, migraines and back pain), have more comorbid psychiatric conditions
(e.g., depression or anxiety), and increased use of psychiatric medications, including
benzodiazepines, antidepressants, and antipsychotics.
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Table 3 presents the results of multivariable logistic regression analysis. The significant
risk factors that were associated with maternal opioid exposure during pregnancy
included: mother’s age at the delivery (18-24 or 25-34 years old), white race, cocaine
use, tobacco use, alcohol use, migraine, low back pain, opioid use prior to pregnancy,
and the year of delivery after 2011. The model fits well (Hosmer and Lemeshow
Goodness-of-Fit Test: P=0.95) with C Statistics at 0.72.

DISCUSSION
From 2008 to 2015, approximately 7.5% of RI Medicaid covered women received at
least one opioid prescription during their pregnancy, and 1 in 4 pregnant women
received opioid medication for an extended duration, which raises concern given the
risks of longer-term opioid use in pregnancy. The increased risk for neonatal abstinence
syndrome or specific cardiovascular and central nervous system defects has been
reported in previous studies.1,2

Although recent studies showed that opioid use in pregnant women decreased
from 14.9% in 2005 to 12.9% in 2011 within the US,5,6 we observed an increased
dispensing of opioids to pregnant women in RI Medicaid that more than doubled from
5% in 2008 to 11% in 2015, with a sharp rise in 2010 and 2011. The overall increase in
the dispensing of prescription opioids directly led to an increase in dispensing of
combination products with hydrocodone, which was dispensed more than all other
prescription opioids. Based on CDC reports in 2010, approximately 16,651 opioid
overdose deaths involved oxycodone, hydrocodone, or methadone. 3 To control for the
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dramatic increase in opioid abuse and overdose deaths, the Drug Enforcement
Administration (DEA) designated hydrocodone combination products from Schedule III
to a more stringently controlled Schedule II category of drug in 2014.7 However, our
results showed that hydrocodone was still the most widely dispensed opioid in pregnant
women on Medicaid in RI in 2014 and 2015.

The opioids most commonly dispensed to RI pregnant women were hydrocodone,
oxycodone, codeine, and tramadol, respectively. In other studies using national claims
data, codeine was a more commonly dispensed opioid in pregnant women.6,8 However,
oxycodone was more widely dispensed to pregnant women in RI than codeine. The
dispensing rates of hydrocodone and oxycodone almost tripled from 2010 to 2011, and
increased more than four-fold for codeine. Prescriptions for hydrocodone also increased
throughout 2011 and 2012, while oxycodone and codeine saw only a relatively small
increases during this period. After 2012, the dispensing rates for these four commonly
used opioids appeared to level off.

Previous studies have demonstrated the risk of teratogenesis for some opioids,
especially when used in the first trimester of pregnancy.1,9 Codeine and hydrocodone
used early in pregnancy have been associated with greater risk of cardiac septal
defects, hypoplastic left heart syndrome, spina bifida, and gastroschisis.1 Oxycodone
has the potential to cause more dependence and overdose. Surprisingly, tramadol,
classified as a pregnancy category C drug by the FDA due to its potential teratogenic
effects suggested by animal studies and as a schedule IV drug by the DEA due to its
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potential for abuse, was also prescribed to pregnant women in RI during the study
period.

Implications for Practice and/or Policy
Most pregnant women experience a variety of pain syndromes (e.g. back pain,
abdominal pain, and migraines) during pregnancy.10 The prevalence of low back or
pelvic pain was 71.7% in pregnancies,11 while migraines were presented in 35% of
pregnancies.12 Providers often face difficult choices when prescribing safe and effective
pain control medications during pregnancy. Non-steroidal anti-inflammatory drugs are a
poor alternative, as they also pose potential harm to both mother and fetus.13 Careful
consideration of the potential benefits and harms of perinatal opioid use is of particular
importance. While opioids are often prescribed they can have adverse effects on the
fetus.1,2

According to the CDC data, RI has a disproportionately high rate of opioid overdose
deaths, (N=320, 31.0% in 2017), which is ninth in the nation.3 RI dispensed the highest
total Morphine Milligram Equivalents (MME) in 2016 (2,623.7 mg/person), more than
two-fold higher than the average total MME in the US.14 It was also noted that Medicaid
enrollees have higher rates of prescription opioid use (22%) compared to commercially
insured patients in the general population (9%).15 Our findings that the rates of opioid
use significantly increased from 2008 to 2015 confirmed that RI Medicaid-covered
pregnant women are at a high risk of opioid use. In March 2017 and July 2018, RI
updated the regulations for Pain Management, Opioid Use, and the Registration of
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Distributors of Controlled Substances.16 The new version of regulations placed stricter
controls on prescribing opioids, including dose limits for initial prescriptions. We expect
to see decreased rates of opioid use in RI in the future.

In some instances the use of opioids for the treatment of pain occurring during
pregnancy is clinically justifiable. For an opioid prescription to be written and given to a
patient, it is required that there is a prescriber-patient relationship and ‘medical need’ for
the medication. In a statement on Opioid Use During Pregnancy, The American College
of Obstetricians and Gynecologists (ACOG) guided that “Opioids should only be used
for treatment of pain when alternatives are not appropriate or effective...”17 Yet the
available literature regarding the safety of opioid use during pregnancy is mixed and
would be better informed by additional and larger cohort studies. A review of the
evidence regarding the short-term and long-term risks of opioid use during pregnancy
reported inconsistent results for studies of fetal development, preterm birth, and birth
defects overall.18 Many of the studies included in this review involved the use of
codeine, which was less frequently utilized in our population. The FDA labels for
oxycodone and hydrocodone note that there are no well-controlled studies in pregnant
women highlighting an important gap in evidence.19 The new CDC’s guideline for
prescribing opioids for chronic pain issued in 2016 suggested that physicians prescribe
non-opioid analgesics or opioids with the lowest dose.20 With the new CDC guideline
and RI regulation for opioid prescribing,16,20 we expect to see the lower prescribing rate
of opioids in RI pregnant women.
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Limitations
Our study has several limitations. First, the use of illicit drugs, including illicit prescription
opioids, was not captured in this study since the prevalence of illicit drug use is not
available in the Medicaid claims data. Second, our data source only collects
prescriptions filled by patients in pharmacies located in RI. Any illicit drug use or opioids
filled in pharmacies outside of RI are not accounted for. Third, expected opioid use was
estimated based on pharmacy claims. Actual utilization in patients may deviate from the
pharmacy dispensing. Fourth, this study is based on the RI Medicaid data. The rates of
opioid use have substantial geographical variations and are significantly different
between Medicaid enrollees and commercially insured patients. 14,15 Therefore, the study
findings can only be generalizable to RI Medicaid enrollees. Lastly, this study only
included women with pregnancies resulting in a live birth. If opioids are associated with
therapeutic or spontaneous terminations of pregnancies, the total opioid use may be
underestimated. Nevertheless, Medicaid pharmacy claims data is seen as the gold
standard of drug exposure compared to outpatient medical records or self-reported drug
use information.

In conclusion, our findings of increasing rates of prescription opioids, filled by pregnant
women enrolled in RI Medicaid, calls for a comprehensive safety assessments of
opioids and their long-term effects on the developing fetus to help inform clinical
practice.
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Figure 1. Percentage of Pregnancies Dispensed Prescription Opioids for Pain.
Rhode Island Medicaid: 2008-2015
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Figure 2. Percent of Prescriptions Per Year for Opioid Types Prescribed for Pregnant
Women in RI Medicaid.
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Table 1. Morphine Milligram Equivalents (MME) and Supply Days for Opioids
Prescribed in RI Women.
Drug Name

Hydrocodone
Oxycodone
Codeine
Tramadol

Average Supply Days
Median (25th percentile, 75th
percentile)
5 (3, 10)
5 (3, 13)
3 (2, 5)
10 (6, 22)

Average MME
Median (25th percentile, 75th
percentile)
25 (20, 38)
45 (30, 71)
27 (18, 45)
20 (15, 32)
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Table 2. Comparison of baseline characteristics of pregnant women in RI Medicaid.
N=25,500.
Characteristics

Maternal Age at delivery
Mean  SD
<18
18-24
25-34
35
Race, N(%)
White
Black
Other
Substance use and abuse
Marijuana
Cocaine
Tobacco use, N(%)
Alcohol use, N(%)
Maternal preexisting condition,
N(%)
Multiple gestation
HIV infection
Depression
Anxiety
Pain conditions
Fibromyalgia
Migraine
Back pain
Psychiatric medications
Anxiolytics
Antidepressants
Antipsychotics
Stimulants
Opioid use at baseline

Exposed to Opioids
during pregnancy
N = 1,914

Unexposed to
Opioids during
pregnancy
N = 23,586

P Value

25.6  8.3
794 (41)
387 (20)
626 (32)
107 (5.6)

25.9  6.3
8,007 (34)
6,914 (29)
7,206 (30.5)
1,459 (6)

0.06
<.0001

<.0001
1,228 (64)
121 (6)
565 (29.5)

12,277 (52)
9,095 (38.6)
2,214 (9.4)

2 (0.1)
8 (0.4)
118 (6.2)
135 (7)

36 (0.15)
16 (0.07)
518 (2.2)
331 (1.4)

0.60
<.0001
<.0001
<.001

29 (3.2)
3 (0.16)
145 (7.6)
50 (2.6)

214 (2.3)
17 (0.07)
1,091 (4.6)
296 (1.3)

0.31
0.19
<.0001
<.0001

39 (2)
175 (9)
231 (12)

117 (0.5)
1,047 (4.4)
955 (4)

<.0001
<.0001
<.0001

106 (5.5)
175 (9)
34 (1.8)
4 (0.2)
311 (16)

355 (1.5)
995 (4.2)
163 (0.69)
57 (0.24)
773 (3)

<.0001
<.0001
<.0001
0.78
<.0001
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Table 3. Significant Risk Factors for Maternal Opioid Use during Pregnancy.
Results of Multivariable Logistic Regression Analysis
Characteristics

Odds Ratio

95% CI
Lower
Upper
Bound
Bound
1.32
2.06

P Value

Mother Race White vs Black

1.65

Cocaine use
Tobacco use
Alcohol Use
Migraines
Low back pain
Benzodiazepine Use
Opioid use prior to pregnancy
Mother Age < 18 vs 18-24
Mother Age 25-34 vs 18-24
Mother Age ≥ 35 vs 18-24
Delivery Year
2015 vs 2008
2014 vs 2008
2013 vs 2008
2012 vs 2008
2011 vs 2008
2010 vs 2008
2009 vs 2008

3.10
1.44
6.38
1.51
1.86
1.60
4.40
0.26
1.45
1.22

1.15
1.12
5.02
1.22
1.52
1.19
3.64
0.13
1.25
0.94

8.36
1.86
8.10
1.88
2.29
2.14
5.32
0.54
1.69
1.59

0.025
0.005
<.0001
0.0002
<.0001
0.0019
<.0001
0.0002
<.0001
0.14

15.89
14.24
1.93
2.64
1.93
0.86
1.03

7.63
6.81
1.52
2.10
1.52
0.64
0.77

33.10
29.76
2.46
3.31
2.46
1.15
1.37

<.0001
<.0001
<.0001
<.0001
<.0001
0.3
0.8

<.0001
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Appendix Table 1. Data Sources and Operational Definitions for Covariates.
Variables
Maternal Age
Race
Marijuana
Cocaine
Tobacco use
Alcohol use
Multiple gestation
HIV infection
Depression
Anxiety
Fibromyalgia
Migraine
Back pain
Anxiolytics Use
Antidepressants Use
Antipsychotics Use
Stimulants Use
Opioid use at baseline

Data Sources
RI DOH Birth Certificates
RI DOH Birth Certificates
RI Medicaid Inpatient/Outpatient
Claims
RI Medicaid Inpatient/Outpatient
Claims
RI Medicaid Inpatient/Outpatient
Claims
RI Medicaid Inpatient/Outpatient
Claims
RI DOH Birth Certificates
RI Medicaid Inpatient/Outpatient
Claims
RI Medicaid Inpatient/Outpatient
Claims
RI Medicaid Inpatient/Outpatient
Claims
RI Medicaid Inpatient/Outpatient
Claims
RI Medicaid Inpatient/Outpatient
Claims
RI Medicaid Inpatient/Outpatient
Claims
RI Medicaid Pharmacy Claims
RI Medicaid Pharmacy Claims
RI Medicaid Pharmacy Claims
RI Medicaid Pharmacy Claims
RI Medicaid Pharmacy Claims

Operational Definitions
Age at delivery
White, Black, and Others
ICD-9 Diagnosis Code
ICD-9 Diagnosis Code
ICD-9 Diagnosis Code
ICD-9 Diagnosis Code

ICD-9 Diagnosis Code
ICD-9 Diagnosis Code
ICD-9 Diagnosis Code
ICD-9 Diagnosis Code
ICD-9 Diagnosis Code
ICD-9 Diagnosis Code
Therapeutic Class Code
Therapeutic Class Code
Therapeutic Class Code
Therapeutic Class Code
Therapeutic Class Code
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